Season 7, Episode 4 - Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?
This episode will explore the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus will be the emerging role of advanced imaging technologies. The discussion will:
- Compare traditional ultrasound with advanced imaging techniques.
- Examine AI-based approaches in patient classification.
The episode will conclude with a forward-looking perspective on the future management of MASLD.
Moderator: Thomas Berg
Faculty: Timm Denecke, Juan-Manuel Pericàs, Valérie Vilgrain
This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.
Related episodes:
EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
EASL Studio S6E1: Do we solve MASLD by treating obesity?
EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
